LCAT Antibody - BSA Free

• Reactivity: Hu, Mu
• Applications: WB, ELISA
• Clonality: Polyclonal
• Host: Rabbit
• Conjugate: Unconjugated
• Format: BSA Free

LCAT Antibody - BSA Free Summary

• Description: Novus Biologicals Rabbit LCAT Antibody - BSA Free (NB400-107) is a polyclonal antibody validated for use in WB and ELISA. Anti-LCAT Antibody: Cited in 7 publications. All Novus Biologicals antibodies are covered by our 100% guarantee.
• Immunogen: Carboxyl-terminal histidine-tagged human recombinant LCAT purified from the medium of CHO cells overexpressing human LCAT cDNA. [UniProt# P04180]
• Isotype: IgG
• Clonality: Polyclonal
• Host: Rabbit
• Gene: LCAT
• Purity: Unpurified

Applications/Dilutions

• Dilutions:
  • ELISA 1:500
  • Western Blot 1:1000
• Application Notes: In Western blot, a band is seen at 62-65 kDa representing LCAT. This antibody does exhibit neutralizing activity for cholesterol esterification.
• Control:

  LCAT Overexpression Lysate

Packaging, Storage & Formulations

• Storage: Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles.
• Buffer: Whole antisera
• Preservative: 0.05% Sodium Azide
• Purity: Unpurified

Alternate Names for LCAT Antibody - BSA Free

• EC 2.3.1.43
• lecithin-cholesterol acyltransferasePhospholipid-cholesterol acyltransferase
• phosphatidylcholine-sterol acyltransferase

Background

Lecithin: cholesterol acyltransferase (LCAT) is the plasma enzyme responsible for most HDL cholesteryl esters in human plasma. In species with cholesteryl ester transfer protein (CETP) it is also responsible for a significant proportion of VLDL and LDL cholesteryl esters. LCAT, through the esterification of cholesterol, plays a role in the reverse cholesterol transport pathway by facilitating the net movement of cholesterol from peripheral tissues back to the liver for excretion. LCAT deficiency results in low levels of plasma HDL, whereas a transgenic overexpression of LCAT results in increased plasma HDL concentrations.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for LCAT Antibody (NB400-107)(7)

Publications using NB400-107

• Aso M, Yamamoto T, Kuroda M et al. First-in-human autologous implantation of genetically modified adipocytes expressing LCAT for the treatment of familial LCAT deficiency Heliyon 2022-11-01 [PMID: 36387451] (WB, Human)
• Sasaki M, Delawary M, Sakurai H et al. Novel LCAT (Lecithin:Cholesterol Acyltransferase) Activator DS-8190a Prevents the Progression of Plaque Accumulation in Atherosclerosis Models Arterioscler Thromb Vasc Biol 2020-10-22 [PMID: 33086872] (WB, Human)
• Khan AMAM, Hauk VJ, Ibrahim M et al. Caldicellulosiruptor bescii adheres to polysaccharides using a type IV pilin-dependent mechanism Appl. Environ. Microbiol. 2020-02-21 [PMID: 32086304] (WB)
• Tanigawa H, Billheimer JT, Tohyama J-i et al. Lecithin: Cholesterol Acyltransferase Expression Has Minimal Effects on Macrophage Reverse Cholesterol Transport In Vivo. Circulation;120(2):160-169. 2009-01-01 [PMID: 19564558] (WB, Human)
• He Y, Greene DJ, Kinter M et al. Control of cholesteryl ester transfer protein activity by sequestration of lipid transfer inhibitor protein in an inactive complex. J Lipid Res;49(7):1529-1537. 2008-01-01 [PMID: 18369235] (WB, Human)
• Zhao Y, Gebre AK, Parks JS. Amino acids 149 and 294 of human lecithin:cholesterol acyltransferase affect fatty acyl specificity. J Lipid Res;45(12):2310-6. 2004-12-01 [PMID: 15375182] (ELISA, Human)
• Chisholm JW, Gebre AK, Parks JS. Characterization of C-terminal histidine-tagged human recombinant lecithin:cholesterol acyltransferase. J Lipid Res;40(8):1512-9. 1999-08-01 [PMID: 10428989]

Bioinformatics

• Gene Symbol: LCAT
• Entrez:
  • 3931(Human)
  • 16816(Mouse)
• Uniprot:
  • P04180(Human)